Table 1.
Cardioprotective effect and mechanism of action of resveratrol in preclinical studies.
Target HDAC or HAT | Molecular pathway | Experimental model | Cardiovascular effect | Reference |
---|---|---|---|---|
↑ Sirt1 | ↑ PGC-1α ↑ Bcl2 ↓ Bax, caspase 3 ↑ SOD, SDH, Cyt-c oxidase |
TAC induced myocardial infraction In vivo Hypoxia induced dysfunction In vitro |
↑ LVEF ↓ fibrosis ↓ apoptosis |
[52] |
↑ Sirt3 | ↓ TGF-β/Smad3 | TAC induced heart failure In vivo |
↓ fibrosis ↓ collagen deposition ↓ cardiac hypertrophy Prevented decrease in cardiac FS Preserved diastolic function |
[53] |
↑ Sirt1 | ↑ SOD | Chronic heart failure model In vivo Ang II or antimycin A induced oxidative stress In vitro |
↑ FS ↑ LVEF ↑ survival ↓ apoptosis |
[54] |
↑ Sirt3 | ↑ SOD | Dox-induced mitochondrial dysfunction In vivo In vitro |
↓ oxidative stress ↑ ATP mitochondrial production |
[32] |
↑ Sirt1 | ↓ p38MAPK ↓ caspase 3 ↓ Bax ↑ Bcl-2 ↑ SOD1 |
Dox-induced heart failure In vivo |
↑ FS ↓ apoptosis ↓ oxidative stress |
[55] |
↑ Sirt1 | ↑ AMPK | Dox-induced cardiotoxicity In vitro |
↑ survival | [56] |
↑ Sirt3 | ↓ p53 ↓ Bax, Cyt-c |
Dox-induced cardiotoxicity In vivo |
↓ apoptosis Attenuated loss of diastolic and systolic function. |
[57] |
↑ Sirt1 | ↓ USP7 ↓ p300 ↓ Bax, caspase 3 ↓ p53 |
Dox-induced cardiotoxicity in young and aged hearts In vivo |
↑ FS ↑ EF ↓ LVEDS ↓ apoptosis |
[58] |
↑ Sirt1 | ↑ PI3K-Akt ↓ TNF-α ↓ FAS/FADD/caspase 8 ↓ caspase 3 ↑ FoxO3 |
Exercise during aging In vivo |
↑ FS ↓ fibrosis ↓ apoptosis |
[41] |
↑ Sirt1 | ↓ ac-FoxO1 ↓ Bim, Bax ↓ p53 |
Aging In vivo |
↑ FS ↑ LVEF ↓ fibrosis ↓ apoptosis |
[40] |
↑ Sirt1 | ↑ SOD ↑ GSH |
High glucose-induced mitochondrial oxidative stress. In vitro |
↓ oxidative stress | [59] |
↑ Sirt1 | ↓ p53 ↑ SDF-1 |
NE-induced hypertrophy In vitro Hypertension model In vivo |
↓ hypertrophy ↑ bioavailable NO ↓ apoptosis |
[60] |
In T1DM: ↑ Sirt1, Sirt2, Sirt3, and Sirt5. In T2DM: ↑ Sirt1 and Sirt2 ↓ Sirt3, which was initially elevated |
↓ B-MHC ↓ Akt |
T1DM-induced cardiomyopathy In vivo T2DM-induced cardiomyopathy In vivo |
In T1DM rats: ↓ cardiac atrophy In T2DM rats: ↓ cardiac hypertrophy |
[61] |
↑ Sirt1, Sirt3, Sirt4, and Sirt7 | ↓ caspase 3 | H2O2-induced apoptosis In vitro |
↓ apoptosis | [62] |
Most effects abolished when using sirtinol | ↑ SOD1, SOD3, GPx1, catalase. ↓ NOX2, NOX4 ↑ GTP cyclohidrolase 1 and biopterin |
In vivo
Apo-lipoprotein E Knockout mice |
↓Oxidative stress Reversed eNOS uncoupling |
[63] |
AMPK: adenosine monophosphate-activated kinase; Ang II: angiotensin II; B-MHC: myosin heavy chain B; Cyt-c: cytochrome c; Dox: doxorubicin; FS: fractional shortening; Gpx1: glutathione peroxidase 1; GSH: glutathione; LVEF: left ventricular ejection fraction; NE: norepinephrine; NOX: NAD(P)H oxidase; PGC1-α: peroxisome proliferator activator of transcription (PPARy) co-activator 1α; TAC: transverse aortic constriction; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; SDF-1: stroma cell derived factor 1; SHD: succinate dehydrogenase; SOD: superoxide dismutase. USP7: ubiquitin-specific-processing protease 7.